Molnupiravir
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
The FDA issued an Emergency Use Authorization (EUA) for the emergency use of molnupiravir for the treatment of mild-to-moderate COVID-19 disease in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19 disease, including hospitalization and death.
- Risk for progression includes: age > 60 years, diabetes, obesity (BMI ≥ 30), chronic kidney disease, serious heart conditions, chronic obstructive pulmonary disease, or active cancer.
- Authorized for treatment within the first 5d of symptomatic COVID-19 illness.
Molnupiravir is NOT authorized for:
- Patients < 18 years of age
- Patients requiring hospitalization for the management of COVID-19 disease (benefit has not been observed in patients beginning treatment after hospitalization)
- Use longer than 5 consecutive days
- Pre-exposure or post-exposure prophylaxis for the prevention of COVID-19 disease
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
The FDA issued an Emergency Use Authorization (EUA) for the emergency use of molnupiravir for the treatment of mild-to-moderate COVID-19 disease in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19 disease, including hospitalization and death.
- Risk for progression includes: age > 60 years, diabetes, obesity (BMI ≥ 30), chronic kidney disease, serious heart conditions, chronic obstructive pulmonary disease, or active cancer.
- Authorized for treatment within the first 5d of symptomatic COVID-19 illness.
Molnupiravir is NOT authorized for:
- Patients < 18 years of age
- Patients requiring hospitalization for the management of COVID-19 disease (benefit has not been observed in patients beginning treatment after hospitalization)
- Use longer than 5 consecutive days
- Pre-exposure or post-exposure prophylaxis for the prevention of COVID-19 disease
There's more to see -- the rest of this entry is available only to subscribers.